The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 660-667

  Chung, Joon Yong ^a   Hong, Seung Mo ^b   Choi, Byeong Yeob ^c   Cho, Hyung Jun ^c   Yu, Eunsil ^d   Hewitt, Stephen M ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Korea University   (South Korea)

^d University of Ulsan   (South Korea)

^e Advanced Technology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DUODENUM CANCER; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY;

AGED; APOPTOSIS; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE;

EID: 59449103646     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1084     Document Type: Article

References (39)

1. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45:856-67.
2. Hong SM, Kim MJ, Pi DY, et al. Analysis of extrahe-patic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients. Cancer 2005;104:802-10.
3. Nagakawa T Kayahara M, Ikeda S, et al. Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 2002;9:569-75.
4. Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol 2007;13:1505-15.
5. Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007;11:1488-96.
6. Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 2007;61:44-51.
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
8. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007;6:2139-48.
9. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 2003;23:6139-49.
10. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
11. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-92.
12. Javle MM, Yu J, Khoury T, et al. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol 2006;21:1744-51.
13. Tanno S, Yanagawa N, Habiro A, et al. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radiore-sistance. Cancer Res 2004;64:3486-90.
14. Hori H, Ajiki T, Mita Y, et al. Frequent activation of mitogen-activated protein kinase relative to Akt in ex-trahepatic biliary tract cancer. J Gastroenterol 2007;42:567-72.
15. Herberger B, Puhalla H, Lehnert M, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007;13:4795-9.
16. Chung JY, Braunschweig T, Baibakov G, et al. Transfer and multiplex immunoblotting of a paraffin embedded tissue. Proteomics 2006;6:767-74.
17. Chung JY, Braunschweig T, Hu N, et al. A multiplex tissue immunoblotting assay for proteomic profiling: a pilot study of the normal to tumor transition of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1403-8.
18. Traicoff JL, Chung JY, Braunschweig T, et al. Expression of EIF3-48/INT6, TID1 and Patched in cancer, a profiling of multiple tumor types and correlation of expression. J Biomed Sci 2007;14:395-405.
19. Chung JY, Braunschweig T. Tuttle K, Hewitt SM. Tissue microarrays as a platform for proteomic investigation. J Mol Histol 2007;38:123-8.
20. Hidalgo A, Pina P, Guerrero G, Lazos M, Salcedo M. A simple method for the construction of small format tissue arrays. J Clin Pathol 2003;56:144-6.
21. Hong SM, Hwang I, Song DE, Choi J, Yu E. Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Mod Pathol 2007;20:562-9.
22. Faried LS, Faried A, Kanuma T et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy. Mol Carcinog. In press 2008.
23. Hong SM, Cho H, Moskaluk CA. Yu E. Measurement of the invasion depth of extrahepatic bile duct carcinoma: an alternative method overcoming the current T classification problems of the AJCC staging system. Am J Surg Pathol 2007;31:199-206.
24. Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006;116:1843-52.
25. Kreisberg Jl, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6.
26. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinico-pathologic study of 292 cases. J Clin Oncol 2005;23:1473-82.
27. Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:2846-50.
28. Tsurutani J, Fukuoka J. Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006;24:306-14.
29. Taylor CR. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 2000;124:945-51.
30. Takikita M, Chung J Y, Hewitt SM. Tissue microarrays enabling high-throughput molecular pathology. Curr Opin Biotechnol 2007;18:318-25.
31. Goldstein NS, Hewitt SM, Taylor CR.Yaziji H, Hicks DG. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 2007;15:124-33.
32. Pineau P, Marchio A, Nagamori S, Seki S. Tiollais P, Dejean A. Homozygous deletion scanning in hepatobiliary tumor cell lines reveals alternative pathways for liver carcinogenesis. Hepatology 2003;37:852-61.
33. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29.
34. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672-6.
35. Kanamori Y, Kigawa J, Itamochi H, et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer 2002;100:686-9.
36. Hu TH, Huang CC, Lin PR, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003;97:1929-40.
37. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.
38. Uegaki K, KanamoriY, Kigawa J,et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005;14:389-92.
39. Sawada T, Okada T, Kubota K. Rapamycin inhibits the growth of cholangiocarcinoma cells in vitro. Proc Am Soc Clin Oncol 2007;25:15153.